For the year ending 2025-12-31, IRWD had $126,897K increase in cash & cash equivalents over the period. $127,010K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 24,017 |
| Depreciation and amortization | 1,881 |
| Loss on disposal of property and equipment | -89 |
| Share-based compensation expense | 17,250 |
| Non-cash interest expense | 1,668 |
| Non-cash lease expense | 1,688 |
| Deferred income taxes | 40,801 |
| Accounts receivable, net | -35,148 |
| Prepaid expenses and other current assets | -367 |
| Other assets | -447 |
| Accounts payable and accrued expenses | 6,201 |
| Accrued research and development costs | -4,106 |
| Operating lease liabilities | -2,371 |
| Other liabilities | 3,964 |
| Net cash provided by operating activities | 127,044 |
| Purchases of property and equipment | 34 |
| Net cash used in investing activities | -34 |
| Proceeds from exercise of stock options and employee stock purchase plan | 216 |
| Net cash provided by (used in) financing activities | 216 |
| Effect of exchange rate changes on cash and cash equivalents | -329 |
| Net increase (decrease) in cash and cash equivalents | 126,897 |
| Cash and cash equivalents, beginning of period | 88,559 |
| Cash and cash equivalents, end of period | 215,456 |
IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD)